Literature DB >> 15319452

Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.

Jennifer H Gutzman1, Debra E Rugowski, Matthew D Schroeder, Jyoti J Watters, Linda A Schuler.   

Abstract

The importance of prolactin (PRL) in physiological proliferation and differentiation of the mammary gland, together with high levels of PRL receptors in breast tumors, the association of circulating PRL with incidence of breast cancer, and the recognition of locally produced PRL, point to the need for greater understanding of PRL actions in mammary disease. Although PRL has been shown to activate multiple kinase cascades in various target cells, relatively little is known of its signaling pathways in the mammary gland apart from the Janus kinase 2/ signal transducer and activator of transcription 5 pathway, particularly in tumor cells. Another potential effector is activating protein-1 (AP-1), a transcription complex that regulates processes essential for neoplastic progression, including proliferation, survival and invasion. We demonstrate that PRL activates AP-1 in MCF-7 cells, detectable at 4 h and sustained for at least 24 h. Although Janus kinase 2 and ERK1/2 are the primary mediators of PRL-induced signals, c-Src, phosphatidylinositol 3'-kinase, protein kinase C, and other MAPKs contribute to maximal activity. PRL activation of these pathways leads to increased c-Jun protein and phosphorylation, JunB protein, and phosphorylation of c-Fos, elevating the levels of AP-1 complexes able to bind DNA. These active AP-1 dimers may direct expression of multiple target genes, mediating some of PRL's actions in mammary disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319452      PMCID: PMC1634796          DOI: 10.1210/me.2004-0187

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  58 in total

1.  Prolactin-induced cell proliferation in PC12 cells depends on JNK but not ERK activation.

Authors:  Y Cheng; I Zhizhin; R L Perlman; D Mangoura
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members.

Authors:  K Milde-Langosch; A M Bamberger; C Methner; G Rieck; T Löning
Journal:  Int J Cancer       Date:  2000-08-15       Impact factor: 7.396

3.  Janus kinase 2-dependent activation of p38 mitogen-activated protein kinase by growth hormone. Resultant transcriptional activation of ATF-2 and CHOP, cytoskeletal re-organization and mitogenesis.

Authors:  T Zhu; P E Lobie
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

4.  Prolactin (PRL)-PRL receptor system increases cell proliferation involving JNK (c-Jun amino terminal kinase) and AP-1 activation: inhibition by glucocorticoids.

Authors:  I Olazabal; J Muñoz; S Ogueta; E Obregón; J P García-Ruiz
Journal:  Mol Endocrinol       Date:  2000-04

Review 5.  Jun, the oncoprotein.

Authors:  P K Vogt
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

6.  Functional characterization of the intermediate isoform of the human prolactin receptor.

Authors:  J B Kline; H Roehrs; C V Clevenger
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

7.  cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

Authors:  L M Smith; S C Wise; D T Hendricks; A L Sabichi; T Bos; P Reddy; P H Brown; M J Birrer
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

8.  Prolactin stimulates activation of c-jun N-terminal kinase (JNK).

Authors:  K L Schwertfeger; S Hunter; L E Heasley; V Levresse; R P Leon; J DeGregori; S M Anderson
Journal:  Mol Endocrinol       Date:  2000-10

9.  Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun.

Authors:  J Rinehart-Kim; M Johnston; M Birrer; T Bos
Journal:  Int J Cancer       Date:  2000-10-15       Impact factor: 7.396

10.  Biological and clinical associations of c-jun activation in human breast cancer.

Authors:  J M Gee; A F Barroso; I O Ellis; J F Robertson; R I Nicholson
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

View more
  17 in total

1.  Identification of NEK3 Kinase Threonine 165 as a Novel Regulatory Phosphorylation Site That Modulates Focal Adhesion Remodeling Necessary for Breast Cancer Cell Migration.

Authors:  Katherine M Harrington; Charles V Clevenger
Journal:  J Biol Chem       Date:  2016-08-03       Impact factor: 5.157

2.  PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin.

Authors:  Jing Tao; Peter Oladimeji; Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-06-30

3.  PAK1 regulates breast cancer cell invasion through secretion of matrix metalloproteinases in response to prolactin and three-dimensional collagen IV.

Authors:  Leah Rider; Peter Oladimeji; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2013-06-06

4.  Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context.

Authors:  J H Gutzman; D E Rugowski; S E Nikolai; L A Schuler
Journal:  Oncogene       Date:  2007-04-16       Impact factor: 9.867

5.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

6.  Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Authors:  Jennifer H Gutzman; Sarah E Nikolai; Debra E Rugowski; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2005-03-03

7.  Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells.

Authors:  Craig E Barcus; Patricia J Keely; Kevin W Eliceiri; Linda A Schuler
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

8.  Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation.

Authors:  Eric Haines; Parham Minoo; Zhenqian Feng; Nazila Resalatpanah; Xin-Min Nie; Manuela Campiglio; Laura Alvarez; Eftihia Cocolakis; Mohammed Ridha; Mauricio Di Fulvio; Julian Gomez-Cambronero; Jean-Jacques Lebrun; Suhad Ali
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

9.  Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.

Authors:  K A O'Leary; D E Rugowski; R Sullivan; L A Schuler
Journal:  Oncogene       Date:  2013-07-22       Impact factor: 9.867

10.  Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.

Authors:  Lisa M Arendt; Lindsay C Evans; Debra E Rugowski; Maria Jose Garcia-Barchino; Hallgeir Rui; Linda A Schuler
Journal:  J Endocrinol       Date:  2009-07-27       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.